FDA Approves J&J's Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease

STRATEGIC NEWS WATCH — August 25, 2026

The FDA approved Johnson & Johnson’s Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia, the first therapy ever shown safe and effective in the disease — a standard approval granted under Priority Review that expands the FcRn blocker beyond its April 2025 myasthenia gravis label and hands J&J a first-mover position it will have to defend against several fast-following rivals.

Today’s top developments:

The FDA approved J&J’s Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia in adults and pediatric patients 12 and older who are or were treated with corticosteroids — the first therapy ever cleared specifically in wAIHA, granted under Priority Review as a standard approval and expanding the FcRn blocker beyond its April 2025 myasthenia gravis label (Pharmaphorum)
Federal courts rejected Merck’s and AstraZeneca’s challenges to Medicare drug price negotiation — Judge Kollar-Kotelly dismissed Merck’s First and Fifth Amendment claims over Januvia on August 24, days after a Maryland judge threw out AstraZeneca’s aggregation argument — leaving the constitutional campaign all but exhausted after the Supreme Court declined five manufacturers’ appeals in May (Fierce Pharma)
McKesson agreed to acquire Precision Medicine Group for $2.25 billion, folding its biomarker intelligence, laboratory, CRO, market access and commercialisation stack into McKesson’s Oncology & Multispecialty segment and pushing the distributor further up the value chain into the services biopharma buys around an oncology launch (Pharmaceutical Executive)
Arch and Population Health Partners — the backers behind Metsera — launched Sentivera with an $83 million financing and in-licensed a Type 2 inflammation small molecule from China’s Haisco for $40 million cash plus ~$36 million in stock, against a $1.5 billion headline that is almost entirely milestone-contingent on an asset with no human efficacy data (Fierce Biotech)
Employer coverage of GLP-1 weight-loss drugs fell to 60% in 2026 from 72% a year earlier, with 14% of employers having dropped it or planning to for 2027, as firms project a 9.2% healthcare cost increase and name cancer their most acute cost driver, per a Business Group on Health survey (Reuters)

What to Watch

Merck and AstraZeneca appeals — Neither company has said whether it will appeal the August 2026 rulings. That decision, and the Teva remand on a generic-marketing question, are now the only live threads with any prospect of narrowing Medicare price negotiation, with the industry’s remaining leverage shifting to the selection methodology and the negotiation process itself.
Imaavy’s competitive window in wAIHA — J&J is first, but Sanofi’s Wayrilz, Hutchmed’s sovleplenib and Zenas’s obexelimab are all in development for the same indication. Payer coverage policy and how quickly a corticosteroid-experienced label converts to real-world use will set the runway before a second entrant arrives.
2027 employer plan design — Open-enrolment decisions land this autumn. The open question is whether the 14% planning to drop GLP-1 coverage grows as employers finalise budgets against a projected 9.2% cost increase, and whether manufacturers answer with further cash-pay price cuts — the demand-side mirror of the supply-side moves.
Distributor-owned services — With Precision Medicine Group inside McKesson, the question is how manufacturers treat a distributor owning a CRO and market access consultancy alongside its distribution and community-oncology relationships — a convenience or a conflict — and whether that concentration draws scrutiny.
Sentivera’s first clinical data — The in-licensed Haisco asset has only just entered clinical development in China. The first human data on a program valued mostly in milestones is the readout that matters, along with whether Arch moves to a large partnership before it arrives.

This brief highlights the edition’s top stories. Read the full August 25, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.

Related Stories

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent